Loading...

ALZN ALZAMEND NEURO INC Capital Structure Changes 8-K Filing

LZMN

LZN

ALZAMEND NEURO INC

(ALZN)

2025 8-K

Show Summary

Show Summary

Bylaws Amendment

Share Exchange Agreement

Financial Results

Nasdaq Compliance

Compliance Regained and Soc...

Amendment to Certificate of...

Special Meeting of Stockhol...

Presentation Update

Annual Meeting Adjournment

Agreement for Sale of Prefe...

Dismissal and Appointment o...

Termination of Agreement

Material Definitive Agreement

Equity Sale and Delisting N...

Warrant Amendment Agreement...

Amended Certificate of Desi...

Agreement with Ault Lending...

Appointment of Director and...

Reverse Stock Split

Delisting Notice

Social Media Communication

Delisting - Non-Compliance

Positive Clinical Trial Res...

Annual Meeting Results

Regulation FD Disclosure

Clinical Trial Initiation

Clinical Trial Completion

Earnings Report

Delisting Notice

Regulation FD Disclosure

External Links:

On May 6, 2025, Alzamend Neuro, Inc. approved a reverse stock split of 1-for-9, reducing outstanding shares from about 7.2 million to approximately 801,000, effective May 12, 2025. This decision was based on stockholder approval from April 25, 2025.

AI Assistant

ALZAMEND NEURO INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.